Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

On the mechanism of miR-29b enhancement of etoposide toxicity in vitro

Z. Dostál, J. Buchtíková, J. Mandrla, M. Modrianský

. 2024 ; 14 (1) : 19880. [pub] 20240827

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019256

Grantová podpora
IGA_LF_2022_025 Univerzita Palackého v Olomouci
RVO 61989592 Univerzita Palackého v Olomouci

MicroRNA hsa-miR-29 was connected to a number of malignancies. Its target genes are many, among them Mcl-1 that is expressed in three possible isoforms, one of which is anti-apoptotic and another one pro-apoptotic. Ratio of these two isoforms appears to affect cell response to external stimuli. We have demonstrated that miR-29b enhanced etoposide toxicity in HeLa cell line by modulating this ratio of Mcl-1 isoforms. However, it is not known whether the described miR-29 effect is common to various cancer types or even have the opposite effect. This represents a significant problem for possible future applications. In this report, we demonstrate that miR-29b affects toxicity of 60 μM etoposide in cell lines derived from selected malignancies. The mechanism, however, differs among the cell lines tested. Hep G2 cells demonstrated similar effect of miR-29b on etoposide toxicity as was described in HeLa cells, i.e. modulation of Mcl-1 expression. Target protein down-regulated by miR-29b resulting in enhanced etoposide toxicity in Caco-2 cells was, however, Bcl-2 protein. Moreover, H9c2, Hek-293 and ARPE-19 cell lines selected as a representatives of non-malignant cells, showed no effect of miR-29b on etoposide toxicity. Our data suggest that miR-29b could be a common enhancer of etoposide toxicity in malignant cells due to its modulation of Bcl family proteins.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019256
003      
CZ-PrNML
005      
20241024111359.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-024-70856-y $2 doi
035    __
$a (PubMed)39191993
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dostál, Zdeněk $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000240028468 $7 xx0267686
245    10
$a On the mechanism of miR-29b enhancement of etoposide toxicity in vitro / $c Z. Dostál, J. Buchtíková, J. Mandrla, M. Modrianský
520    9_
$a MicroRNA hsa-miR-29 was connected to a number of malignancies. Its target genes are many, among them Mcl-1 that is expressed in three possible isoforms, one of which is anti-apoptotic and another one pro-apoptotic. Ratio of these two isoforms appears to affect cell response to external stimuli. We have demonstrated that miR-29b enhanced etoposide toxicity in HeLa cell line by modulating this ratio of Mcl-1 isoforms. However, it is not known whether the described miR-29 effect is common to various cancer types or even have the opposite effect. This represents a significant problem for possible future applications. In this report, we demonstrate that miR-29b affects toxicity of 60 μM etoposide in cell lines derived from selected malignancies. The mechanism, however, differs among the cell lines tested. Hep G2 cells demonstrated similar effect of miR-29b on etoposide toxicity as was described in HeLa cells, i.e. modulation of Mcl-1 expression. Target protein down-regulated by miR-29b resulting in enhanced etoposide toxicity in Caco-2 cells was, however, Bcl-2 protein. Moreover, H9c2, Hek-293 and ARPE-19 cell lines selected as a representatives of non-malignant cells, showed no effect of miR-29b on etoposide toxicity. Our data suggest that miR-29b could be a common enhancer of etoposide toxicity in malignant cells due to its modulation of Bcl family proteins.
650    _2
$a lidé $7 D006801
650    12
$a etoposid $x toxicita $x farmakologie $7 D005047
650    12
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    12
$a protein MCL-1 $x genetika $x metabolismus $7 D064549
650    _2
$a HeLa buňky $7 D006367
650    _2
$a apoptóza $x účinky léků $x genetika $7 D017209
650    _2
$a protoonkogenní proteiny c-bcl-2 $x genetika $x metabolismus $7 D019253
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a fytogenní protinádorové látky $x farmakologie $x toxicita $7 D000972
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a Caco-2 buňky $7 D018938
655    _2
$a časopisecké články $7 D016428
700    1_
$a Buchtíková, Jana $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Mandrla, Jan $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Modrianský, Martin $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. martin.modriansky@upol.cz $1 https://orcid.org/0000000176920338 $7 xx0042117
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 19880
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39191993 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111353 $b ABA008
999    __
$a ok $b bmc $g 2201853 $s 1231229
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 1 $d 19880 $e 20240827 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a IGA_LF_2022_025 $p Univerzita Palackého v Olomouci
GRA    __
$a RVO 61989592 $p Univerzita Palackého v Olomouci
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...